Note 8 - Segment Reporting (Tables)

3 Months Ended

Sep. 30, 2017

Notes Tables

Reconciliation of Revenue from Segments to Consolidated [Table Text Block]

	Three Months Ended September 30, 2017
	Clinical Development			Device			Total
Net revenues	$	126,000		$	2,943,000		$	3,069,000
Cost of revenues		120,000			2,018,000			2,138,000
Gross profit		6,000			925,000			931,000
Operating expenses		1,169,000			2,112,000			3,281,000
Operating loss	$	(1,163,000	)	$	(1,187,000	)	$	(2,350,000	)
Depreciation and amortization	$	75,000		$	85,000		$	160,000
Stock-based compensation expense	$	85,000		$	47,000		$	132,000

	Three Months Ended September 30, 2016
	Clinical Development			Device		Total
Net revenues	$	156,000		$	3,611,000	$	3,767,000
Cost of revenues		142,000			2,243,000		2,385,000
Gross profit		14,000			1,368,000		1,382,000
Operating expenses		1,964,000			1,366,000		3,330,000
Operating profit (loss)	$	(1,950,000	)	$	2,000	$	(1,948,000	)
Depreciation and amortization	$	139,000		$	122,000	$	261,000
Stock-based compensation expense	$	190,000		$	108,000	$	298,000